(MT Newswires) -- Kasim Kutay, CEO of Novo Holdings, has announced that the group is to step up its M&A activity, with a particular focus on the life sciences and healthcare sector. The company is looking to avoid areas already covered by Novo Nordisk, such as obesity. Novo Nordisk aims to steer investments through to the end of the decade, with a strong focus on Asian markets, despite high valuations.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
920.8 DKK | +0.11% | -0.63% | +31.99% |
12:00pm | Weight-loss drug forecasts jump to $150 billion as supply grows | RE |
11:36am | NOVO NORDISK : Deutsche Bank reaffirms its Buy rating | ZD |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+31.99% | 59TCr | |
+38.51% | 73TCr | |
-6.23% | 35TCr | |
+18.78% | 33TCr | |
+1.35% | 28TCr | |
+14.77% | 24TCr | |
+7.74% | 21TCr | |
-6.01% | 20TCr | |
+6.19% | 16TCr | |
+0.31% | 16TCr |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Kasim Kutay, CEO of Novo Holdings: Acquisition Offensive